Biotech entity
Every one of those 1 sits in a single category, pharma. Center for Biological Diversity is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Noah Greenwald, all published on July 18, 2026.
Last mentioned: Jul 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Center for Biological Diversity is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Noah Greenwald, all published on July 18, 2026. Each carries 9 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Noah Greenwald. Shared-story counts are live from our verified record — not editorial picks.
The U.S. Interior Department’s cancellation of automatic ESA protections for threatened species could accelerate biodiversity loss, directly threatening the natural sources of many pharmaceuticals. Bioprospecting and natural product R&D face heightened uncertainty as habitat destruction outpaces species discovery. The rule change adds regulatory complexity for biotech companies seeking access to rare organisms.
Noah Greenwald is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
